Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vical Inc.
Brickell’s Phase III Data Sets Up NDA Filing In Axillary Hyperhidrosis
Meeting all primary and secondary endpoints in a pair of pivotal trials, Brickell says sofpironium bromide gel will be ready for FDA filing in mid-2022. The topical is already approved in Japan as Ecclock.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.